Recent Posts
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual MeetingMarch 23, 2023
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myelomaMarch 16, 2023
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanomaFebruary 2, 2023